Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose versus standard-dose quadrivalent influenza vaccine in adults aged 65 years and older
2019-001401-25Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Jul 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of quadrivalent influenza vaccine and Vaxigrip in influenza (2 arms), sponsored by Sanofi. Primary endpoint: Number of unscheduled cardiovascular or respiratory inpatient hospitalizations. Started Jul 2019; status: terminated.
02
Drugs
quadrivalent influenza vaccineVaxigrip
03
Conditions
influenza
Beyond the preview
Go deeper on 2019-001401-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001401-25.